Cargando…
Positioning new pharmacotherapies for COPD
COPD imposes considerable worldwide burden in terms of morbidity and mortality. In recognition of this, there is now extensive focus on early diagnosis, secondary prevention, and optimizing medical management of the disease. While established guidelines recognize different grades of disease severity...
Autores principales: | Barjaktarevic, Igor Z, Arredondo, Anthony F, Cooper, Christopher B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521666/ https://www.ncbi.nlm.nih.gov/pubmed/26244017 http://dx.doi.org/10.2147/COPD.S83758 |
Ejemplares similares
-
The use of nebulized pharmacotherapies during the COVID-19 pandemic
por: Sethi, Sanjay, et al.
Publicado: (2020) -
Pharmacotherapies for COPD
por: Ejiofor, Stan, et al.
Publicado: (2013) -
Nebulized Therapies in COPD: Past, Present, and the Future
por: Barjaktarevic, Igor Z, et al.
Publicado: (2020) -
Bronchodilator responsiveness or reversibility in asthma and COPD – a need for clarity
por: Barjaktarevic, Igor, et al.
Publicado: (2018) -
Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities
por: Matera, Maria Gabriella, et al.
Publicado: (2023)